Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)

Kangstem Biotech

Status: Enrolling

Conditions: Rheumatoid Arthritis

Treatments: Other: Not applicable(observational study)

Study type: Observational

Funder types: Industry

Identifiers

NCT04134169

K0202-E

Details and patient eligibility

About

Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)

Full description

A Multi-center, Open, Long-term Follow-up Study to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid arthritis: 5-year Results From the K0202 Extension Study

Enrollment: 28 estimated patients

Sex: All

Ages: 19 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subject who enrolled K0202 Clinical Trial(parent study) and has been given more than one medication.
2. Subjects who understand and voluntarily sign an informed consent form

Exclusion criteria

1. Any other condition which the investigator judges would make patient unsuitable for study participation

Trial design

28 participants in 1 patient group

Rheumatoid arthritis

Treatment:

Other: Not applicable(observational study)